{"id":3587,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2000-08-09","marketCap":12.777451515197754,"name":"Plus Therapeutics Inc","phone":"17372557194","outstanding":4.28000020980835,"symbol":"PSTV","website":"http://www.plustherapeutics.com/","industry":"Biotechnology"},"price":2.245175,"year":2024,"month":5,"day":18,"weekday":"Saturday","title":"Sentiment Analysis of Analysts and Financial Experts for Plus Therapeutics Inc Stock","date":"2024-05-18","url":"/posts/2024/05/18/PSTV","content":[{"section":"Price Targets","text":"Price targets for Plus Therapeutics Inc stock vary among analysts and financial experts. Some analysts have set a high price target, expecting the stock to perform well and reach a significant valuation. On the other hand, there are analysts with lower price targets, indicating a more conservative outlook for the stock's potential."},{"section":"Recommendations","text":"Analysts and financial experts have diverse recommendations for Plus Therapeutics Inc stock. Some analysts recommend buying the stock, indicating a positive sentiment and belief in its future growth. However, there are also analysts who recommend holding or selling the stock, expressing a more cautious stance or concern about its performance."},{"section":"Summary of Analyst Opinions","text":"Overall, the sentiment among analysts and financial experts is mixed regarding Plus Therapeutics Inc stock. There are differing price targets and recommendations, reflecting uncertainty and varied expectations for the stock's performance. It is advisable for investors to carefully consider the analysis and recommendations of multiple experts before making investment decisions."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1715979600,"headline":"Plus Therapeutics Announces New Employment Inducement Grants","id":127765043,"image":"https://s.yimg.com/ny/api/res/1.2/ybMmJid1wix7m56kIBhBVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02ODc-/https://media.zenfs.com/en/globenewswire.com/074aebb13f06b6153b38a42de867fde2","symbol":"PSTV","publisher":"Yahoo","summary":"AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that on May 8, 2024, it granted option awards to Charles Huang, the Company’s new Director of Capital Markets and Investor Relations. The Company agreed to grant these equity awards to Mr. Huang to induce him to commence emp","url":"https://finance.yahoo.com/news/plus-therapeutics-announces-employment-inducement-210000064.html"},{"category":"company","date":1715907840,"headline":"Plus Therapeutics at Risk of Nasdaq Delisting: A Dive into Compliance Challenges and Potential Market Impact","id":127757012,"image":"","symbol":"PSTV","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500108600"},{"category":"company","date":1715843132,"headline":"Plus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...","id":127734901,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"PSTV","publisher":"Yahoo","summary":"Explore key financial shifts, strategic acquisitions, and clinical advancements as PSTV navigates its Q1 2024 landscape.","url":"https://finance.yahoo.com/news/plus-therapeutics-inc-pstv-q1-070532150.html"},{"category":"company","date":1715807883,"headline":"Plus Therapeutics, Inc. (PSTV) Q1 2024 Earnings Call Transcript","id":127722844,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"PSTV","publisher":"SeekingAlpha","summary":"Plus Therapeutics, Inc. (NASDAQ:NASDAQ:PSTV) Q1 2024 Earnings Conference Call May 15, 2024 5:00 PM ETCompany ParticipantsMarc Hedrick - President and Chief...","url":"https://seekingalpha.com/article/4693692-plus-therapeutics-inc-pstv-q1-2024-earnings-call-transcript"},{"category":"company","date":1715804100,"headline":"Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights","id":127723777,"image":"https://s.yimg.com/ny/api/res/1.2/ybMmJid1wix7m56kIBhBVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02ODc-/https://media.zenfs.com/en/globenewswire.com/074aebb13f06b6153b38a42de867fde2","symbol":"PSTV","publisher":"Yahoo","summary":"Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive top-line FORESEE clinical trial data Management to Host Conference Call May 15, 2024 at 5:00 p.m. ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a cl","url":"https://finance.yahoo.com/news/plus-therapeutics-reports-first-quarter-201500779.html"},{"category":"company","date":1715791200,"headline":"Plus: Q1 Earnings Snapshot","id":127725150,"image":"","symbol":"PSTV","publisher":"Associated Press, The","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=eia0j306c8"},{"category":"company","date":1715759640,"headline":"PSTV Stock Earnings: Plus Therapeutics Beats EPS, Misses Revenue for Q1 2024","id":127725154,"image":"","symbol":"PSTV","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3497834095"},{"category":"company","date":1715744280,"headline":"Plus Therapeutics reports Q1 EPS (75c), consensus ($1.09)","id":127725155,"image":"","symbol":"PSTV","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3497391043"},{"category":"company","date":1715743680,"headline":"Plus Therapeutics GAAP EPS of -$0.75 beats by $0.34, revenue of $1.67M misses by $0.02M","id":127725156,"image":"","symbol":"PSTV","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3497372762"},{"category":"company","date":1715661540,"headline":"Notable earnings after Wednesday's close","id":127690788,"image":"","symbol":"PSTV","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3495606066"},{"category":"company","date":1715661540,"headline":"Plus Therapeutics Q1 2024 Earnings Preview","id":127725157,"image":"","symbol":"PSTV","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3495606054"},{"category":"company","date":1715599800,"headline":"Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024","id":127660714,"image":"https://s.yimg.com/ny/api/res/1.2/ybMmJid1wix7m56kIBhBVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02ODc-/https://media.zenfs.com/en/globenewswire.com/074aebb13f06b6153b38a42de867fde2","symbol":"PSTV","publisher":"Yahoo","summary":"AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 15, 2024, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the finan","url":"https://finance.yahoo.com/news/plus-therapeutics-announce-first-quarter-113000656.html"},{"category":"company","date":1715326860,"headline":"Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Plus Therapeutics (PSTV) and Argenx Se (ARGX)","id":127621100,"image":"","symbol":"PSTV","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3488923801"},{"category":"company","date":1715268540,"headline":"Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial","id":127585300,"image":"https://s.yimg.com/ny/api/res/1.2/ybMmJid1wix7m56kIBhBVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02ODc-/https://media.zenfs.com/en/globenewswire.com/074aebb13f06b6153b38a42de867fde2","symbol":"PSTV","publisher":"Yahoo","summary":"Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, “CNSide™” and discussed potential partnering opportunities CNSide can significantly improve LM diagnostic accuracy and the market size for Plus’ lead LM radiotherapeutic candidate rhenium (Re186) obisbemeda Company summarized topline data from the FORESEE clinical trial planned for complete presentation at the SNO/ASCO Meeting in August 2024 Call replay \u0026 transcript available via the link below AUSTIN","url":"https://finance.yahoo.com/news/plus-therapeutics-provides-highlights-regarding-152900337.html"},{"category":"company","date":1715249220,"headline":"Biotech Alert: Searches spiking for these stocks today","id":127572610,"image":"","symbol":"PSTV","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3486660336"},{"category":"company","date":1715204100,"headline":"Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial","id":127555362,"image":"https://s.yimg.com/ny/api/res/1.2/ybMmJid1wix7m56kIBhBVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02ODc-/https://media.zenfs.com/en/globenewswire.com/074aebb13f06b6153b38a42de867fde2","symbol":"PSTV","publisher":"Yahoo","summary":"Company acquired all assets for the synergistic CNSide cerebrospinal fluid diagnostic portfolio Company will summarize topline data from the FORESEE clinical trial planned for presentation at the SNO/ASCO Meeting in August 2024 Management call scheduled for Thursday, May 9th, 2024 at 8:30 AM ET AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform","url":"https://finance.yahoo.com/news/plus-therapeutics-host-investor-call-213500697.html"},{"category":"company","date":1714995000,"headline":"Plus Therapeutics Announces Private Placement Financing of up to $18 Million","id":127480452,"image":"https://s.yimg.com/ny/api/res/1.2/ybMmJid1wix7m56kIBhBVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02ODc-/https://media.zenfs.com/en/globenewswire.com/074aebb13f06b6153b38a42de867fde2","symbol":"PSTV","publisher":"Yahoo","summary":"$6.5 million in upfront gross proceeds with the potential to receive up to an additional $11.5 million in potential warrant exercise proceeds for an aggregate of up to approximately $18 million in total gross proceedsAUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it","url":"https://finance.yahoo.com/news/plus-therapeutics-announces-private-placement-113000488.html"},{"category":"company","date":1714979220,"headline":"Plus Therapeutics looks to raise $18 million through private placement","id":127486310,"image":"","symbol":"PSTV","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3479682649"},{"category":"company","date":1714977720,"headline":"Plus Therapeutics announces up to $18M private placement financing","id":127486311,"image":"","symbol":"PSTV","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3479657874"}]}